盟科药业：上半年营收同比增长10.26% 净利润大幅减亏

Core Viewpoint - The company reported a significant reduction in losses and a steady increase in revenue, driven by ongoing innovation and market expansion in the pharmaceutical sector [1][2]. Financial Performance - In the first half of 2025, the company achieved revenue of 66.97 million yuan, a year-on-year increase of 10.26% [1]. - The net profit attributable to shareholders was a loss of 139 million yuan, which represents a substantial decrease of 31.11% compared to the previous period [1]. - Gross profit reached 56.78 million yuan, reflecting a 14.7% year-on-year growth, with a gross margin improvement of 3.28 percentage points to 84.79% [1]. Product Development and Pipeline - The company has a robust research pipeline, including one marketed drug, four in clinical stages, and several in preclinical research [1]. - The new generation oxazolidinone antibiotic, MRX-4, has had its market application accepted by the National Medical Products Administration in May 2025 [2]. - A multi-center, randomized, double-blind Phase III clinical trial is underway to evaluate the efficacy and safety of MRX-4 compared to oral administration of the antibiotic linezolid for treating drug-resistant Gram-positive bacterial infections in adults [2]. - The international multi-center Phase III clinical trial for MRX-4 sequential therapy with the oral formulation for diabetic foot infections has been approved in over 20 countries, with 465 patients enrolled [2]. - The company is also advancing the development of MRX-8 for treating resistant Gram-negative bacterial infections and exploring an inhalation formulation for chronic lung infections [2]. - The new drug MRX-5 for non-tuberculous mycobacterial infections has received orphan drug designation from the FDA, with a Phase I clinical trial ongoing in China involving 19 healthy subjects [2]. Market Presence and Academic Influence - The company showcased its core product, MRX-4, and several pipeline products at various domestic and international conferences, enhancing its academic influence in the global pharmaceutical innovation field [3].